Tricyclic compounds and compositions as kinase inhibitors

US10377770B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Robert John Aversa · Cambridge, US
• Matthew Burger · Belmont, US
• Michael Patrick Dillon · Mill Valley, US
• Thomas A. Dineen · Somerville, US
• Rajesh Karki · Quincy, US
• Savithri Ramurthy · Walnut Creek, US
• Vivek Rauniyar · Cambridge, US
• Richard J. Robinson · Cambridge, US
• Patrick James Sarver · Princeton, US

Key dates

• Filing date: Dec 15, 2016
• Grant date: Aug 13, 2019
• Expiry date: Dec 15, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D491/044
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention provides compounds of Formula (A): (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent, and methods of using the compositions and combinations to treat conditions including cancers.